Rekha Arya

1. Host-pathogen interactions High throughout drug screening (HTS) 
2. Drug repositioning/repurposing 
3. Novel Anti-virulent drug screening 
4. Biomarker assays 
5. In-vitro drug validation Animal infection models 
6. In-vivo drug efficacy studies In-vivo pharmacological studies 
7. Drug toxicity testing
8. Pharmacological analysis of drug-immune interactions

1. Exploring host pathogen interactions and human diseases by
   genome wide next generation dual RNA sequencing (
2. Multiomics based target identification for next generation
   antimicrobial and anti virulent therapies
3. High throughput screening of plant derived compounds and FDA
   approved drug libraries targeting global regulators to develop
   novel anti virulent drugs against multi drug resistant bacteria
4. Understanding the anti virulent immune interaction and their
   synergy to treat bacterial infections
5. Development of various animal infection models including MDR S
   aureus induced infective endocarditis, dermonecrosis and sepsis
6. Evaluation of small molecule inhibitors and its derivatization
7. Combinatorial approach to sensitize the multiple drug resistant
   bacteria against existing antibiotics 

I have not been taken any training